Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma.

Within the intention-to-treat (ITT) population, nine patients completed six cycles of VAD, while eight, one and one patient each discontinued treatment due to disease progression, adverse events or death, respectively. Six of twelve patients with documented disease progression received subsequent anti-lymphoma treatment at the investigator's discretion. However, considering the incurable nature of MCL even with modern therapies,[6] the findings of BATMAN suggest that VAD may be a viable second- or later-line therapy for RRMCL. Despite recent advancements in frontline therapies, most mantle cell lymphoma (MCL) patients inevitably relapse.[1] Bruton's tyrosine kinase (BTK) inhibitors exhibit potent efficacy for relapsed or refractory MCL (RRMCL).[[2], [4]] However, these agents rarely cure the disease, requiring subsequent salvage treatments in many patients. [Extracted from the article]